C. Klebanoff

发表

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

C. Brennan, M. Ladanyi, M. Berger, 2019, Nature Genetics.

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.

W. Leonard, S. Rosenberg, C. Klebanoff, 2008, Blood.

Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function.

P. Muranski, C. Klebanoff, A. Lal, 2013, The Journal of clinical investigation.

Ionic immune suppression within the tumour microenvironment limits T cell effector function

W. Linehan, K. Okkenhaug, Jenny H. Pan, 2016, Nature.

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.

S. Steinberg, S. Rosenberg, D. Citrin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

S. Rosenberg, C. Klebanoff, N. Restifo, 2005, The Journal of clinical investigation.

Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

S. Rosenberg, P. Muranski, C. Klebanoff, 2011, Clinical Cancer Research.

Prospects for gene-engineered T cell immunotherapy for solid cancers

S. Rosenberg, C. Klebanoff, N. Restifo, 2016, Nature Medicine.

Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.

M. Sabatino, C. Klebanoff, D. Stroncek, 2016, Blood.

Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy.

C. Klebanoff, R. Siegel, Fei Yi, 2018, Trends in molecular medicine.

Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA

Ilinca Ş. Aricescu, Doron Betel, A. Drilon, 2022, Nature Medicine.

Immunogenicity of a public neoantigen derived from mutated PIK3CA

Doron Betel, D. Scheinberg, B. Weigelt, 2021, bioRxiv.

The transcriptional program of vaccine-induced CD8 + T cell memory

G. Nabel, C. Klebanoff, M. Cameron, 2014 .

Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo1

C. Klebanoff, N. Restifo, D. Palmer, 2006, The Journal of Immunology.

Tolerance and Immunity In Vivo Interleukin-2-Dependent Mechanisms of

C. Klebanoff, N. Restifo, D. Palmer, 2006 .

Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits CD8+ T cell memory formation

F. Marincola, P. Muranski, C. Klebanoff, 2011, Nature Immunology.

Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction1

C. Klebanoff, J. Yang, N. Restifo, 2004, The Journal of Immunology.

Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance

F. Marincola, C. Klebanoff, E. Wang, 2015, Journal for ImmunoTherapy of Cancer.

Cish actively silences tcr signaling in CD8+ T cells to maintain tumor tolerance

C. Klebanoff, L. Samelson, L. Balagopalan, 2015, Journal of Immunotherapy for Cancer.

subsets possess superior traits for adoptive immunotherapy T cells derived from naive rather than memory + Human effector CD8

W. Burns, P. Muranski, C. Klebanoff, 2011 .

Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma

S. Rosenberg, C. Klebanoff, J. Yang, 2014 .

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy

B. A. Aksoy, C. Klebanoff, J. Hammerbacher, 2019, The Journal of clinical investigation.

Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.

C. Klebanoff, D. Stroncek, M. Kruhlak, 2017, JCI insight.

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

F. Marincola, S. Rosenberg, P. Muranski, 2015, The Journal of clinical investigation.

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.

A. K. Srivastava, M. Raffeld, S. Rosenberg, 2017, The Lancet. Oncology.

T cells and IFN-γ. These findings demonstrate that BACH2 is a key component of the molecular program of tumor immunosuppression and identify therapeutic targets for the reversal of immunosuppression in cancer. The transcription factor BACH2 promotes tumor immunosuppression

F. Marincola, K. Okkenhaug, Jenny H. Pan, 2016 .

The transcription factor BACH2 promotes tumor immunosuppression.

F. Marincola, K. Okkenhaug, Jenny H. Pan, 2016, The Journal of clinical investigation.

Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy

C. Klebanoff, R. Brentjens, S. Rafiq, 2020, Cancer Immunology Research.

obviates the requirement for in vivo vaccination T cells in vitro + Programming tumor-reactive effector memory CD8

C. Klebanoff, N. Restifo, L. Gattinoni, 2013 .

Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

C. Klebanoff, N. Restifo, L. Gattinoni, 2009, Blood.

Pharmacologic Induction of CD8+ T Cell Memory: Better Living Through Chemistry

C. Klebanoff, N. Restifo, L. Gattinoni, 2009, Science Translational Medicine.

Stubborn Tregs limit T-cell therapy.

C. Klebanoff, L. Gattinoni, 2012, Blood.

2352 2 0 S E P T E M B E R 2 0 1 2 I V O L U M E 1 2 0 , N U M B E R 1 2 Blood

W. Kuehl, C. Klebanoff, L. Gattinoni, 2022 .

Destruction TumorUbiquitously while Mediating Specific T Cells Traffic Indiscriminately and + CD 8 Vaccine-Stimulated , Adoptively Transferred

C. Klebanoff, J. Yang, N. Restifo, 2004 .

Treatment of metastatic uveal melanoma with adoptive transfer of tumor infiltrating lymphocytes: a single-center phase 2 study

A. K. Srivastava, M. Raffeld, S. Rosenberg, 2017 .

Cancer Therapy : Preclinical Determinants of Successful CD 8 þ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

S. Rosenberg, P. Muranski, C. Klebanoff, 2011 .

Retinoic acid controls the homeostasis of pre-cDC–derived splenic and intestinal dendritic cells

Y. Belkaid, R. Danner, P. Muranski, 2013, The Journal of experimental medicine.

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

S. Rosenberg, C. Klebanoff, N. Restifo, 2005, The Journal of experimental medicine.

Interleukin-2-dependent mechanisms of tolerance and immunity in vivo

C. Klebanoff, N. Restifo, D. Palmer, 2006, The Journal of Immunology.

Risk stratification of cardiac metastases using late gadolinium enhancement cardiovascular magnetic resonance: prognostic impact of hypo-enhancement evidenced tumor avascularity

R. Kim, J. Weinsaft, M. Ginsberg, 2021, Journal of Cardiovascular Magnetic Resonance.

CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer

Amanda R. Kulick, C. Rudin, J. Wolchok, 2022, bioRxiv.

A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers

S. Rosenberg, C. Klebanoff, J. Yang, 2018, Clinical Cancer Research.

Evidence suggesting persistence of nephritogenic immunopathologic mechanisms in patients receiving renal allografts.

C. Klebanoff, A. Cosimi, R. Lordon, 1973, The Journal of clinical investigation.

Normalized Synergy Predicts That CD8 Co-Receptor Contribution to T Cell Receptor (TCR) and pMHC Binding Decreases As TCR Affinity Increases in Human Viral-Specific T Cells

C. Klebanoff, S. Eckhardt, Tori N. Yamamoto, 2017, Frontiers in immunology.

Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration.

E. Dmitrovsky, D. Munn, J. Tolar, 2013, Blood.

Title: Optimization of T-cell receptor–modified T cells for cancer therapy

C. Klebanoff, R. Brentjens, S. Rafiq, 2020 .

Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma.

J. Friedberg, S. Rosenberg, C. Klebanoff, 2016 .

Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies

S. Rosenberg, P. Muranski, C. Klebanoff, 2011, Journal of immunotherapy.

for adoptive immunotherapy T cells + IL-2 and IL-21 confer opposing differentiation programs to CD8

W. Leonard, S. Rosenberg, C. Klebanoff, 2010 .

Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance

F. Marincola, C. Klebanoff, E. Wang, 2015, Journal for ImmunoTherapy of Cancer.

Erasing iatrogenic neoantigens from in vivo CRISPR screens.

C. Klebanoff, Fei Yi, 2021, Immunity.

Association of PI3K Pathway Mutations with Early PET/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single Center Retrospective Pilot Study

E. Ziv, S. Chandarlapaty, L. Brody, 2019 .

Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

Tamara J Laskowski, J. Taube, P. Ascierto, 2022, Journal of Translational Medicine.

Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

S. Rosenberg, C. Klebanoff, N. Restifo, 2003, The Journal of experimental medicine.

Clinical implications of T cell exhaustion for cancer immunotherapy

J. Wolchok, C. Klebanoff, A. Chow, 2022, Nature Reviews Clinical Oncology.

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

D. Karlis, G. Coukos, U. Dafni, 2019 .

BACH2 represses effector programmes to stabilize Treg-mediated immune homeostasis - a new target in tumor immunotherapy?

F. Marincola, D. Bedognetti, B. Dema, 2013, Journal of Immunotherapy for Cancer.

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.

S. Rosenberg, C. Klebanoff, J. Yang, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Adoptive Therapy with Tumor-infiltrating Lymphocytes and Recombinant Interleukin-2 in Advanced Cutaneous Melanoma: A Systematic Review and Meta-analysis.

D. Karlis, G. Coukos, U. Dafni, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells

T. Waldmann, S. Rosenberg, C. Klebanoff, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Genetic editing of CISH enhances T cell effector programs independently of immune checkpoint cell surface ligand expression

Beau R. Webber, C. Klebanoff, B. Moriarity, 2021 .

T cell stemness and dysfunction in tumors are triggered by a common mechanism

J. Locasale, C. Klebanoff, Jing Huang, 2019, Science.

Paths to stemness: building the ultimate antitumour T cell

C. Klebanoff, N. Restifo, L. Gattinoni, 2012, Nature Reviews Cancer.

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

Mark S. Sundrud, F. Marincola, S. Rosenberg, 2015, Cancer research.

TOX is a critical regulator of tumour-specific T cell differentiation

Yong Liu, M. Glickman, N. Altorki, 2019, Nature.

BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers

Yuka Kanno, Yun Ji, Yoshiyuki Wakabayashi, 2016, Nature Immunology.

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance

C. Klebanoff, Smita S Chandran, 2019, Immunological reviews.

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer

B. Howie, J. Gartner, S. Rosenberg, 2017, Science.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)

R. Sullivan, P. Ascierto, J. Brugarolas, 2018, Journal of Immunotherapy for Cancer.

Shared cancer neoantigens: Making private matters public

J. Wolchok, C. Klebanoff, Jedd D Wolchok, 2018, The Journal of experimental medicine.

Th17 cells are long lived and retain a stem cell-like molecular signature.

S. Kern, R. Danner, P. Muranski, 2011, Immunity.

Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study.

E. Ziv, S. Chandarlapaty, L. Brody, 2018, Journal of vascular and interventional radiology : JVIR.

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

T. Doman, M. Morris, J. Durack, 2020, Clinical Cancer Research.

Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy?

C. Klebanoff, N. Restifo, L. Gattinoni, 2012, Journal of immunotherapy.

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.

T. Waldmann, S. Rosenberg, C. Klebanoff, 2005, Proceedings of the National Academy of Sciences of the United States of America.

The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.

Amanda R. Kulick, C. Rudin, J. Wolchok, 2022, Immunity.

Leveraging CD39 To Identify Tumor-Reactive CD8 T cells In Human Lung Cancer

Maria R. Ward, Amanda R. Kulick, C. Rudin, 2022 .

CD8+ T‐cell memory in tumor immunology and immunotherapy

C. Klebanoff, N. Restifo, L. Gattinoni, 2006, Immunological reviews.

Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

Tamara J Laskowski, J. Taube, P. Ascierto, 2022, Journal of translational medicine.

Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform

D. Scheinberg, C. Klebanoff, Aaron Y. Chang, 2020, Cancer Immunology Research.

Treatment of metastatic human papillomavirus-associated epithelial cancers with adoptive transfer of tumor-infiltrating T cells.

S. Rosenberg, C. Klebanoff, J. Yang, 2018 .

Therapeutic cancer vaccines: are we there yet?

C. Klebanoff, N. Restifo, Zhiya Yu, 2011, Immunological reviews.

Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche

Y. Belkaid, A. Goldrath, C. Klebanoff, 2016, Cell.

Silencing stemness in T cell differentiation

C. Klebanoff, N. Restifo, A. Henning, 2018, Science.

Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape

F. Marincola, Manikandan Narayanan, Suresh Cuddapah, 2015, Cellular and Molecular Immunology.

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

J. Friedberg, S. Rosenberg, C. Klebanoff, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

C. Brennan, M. Ladanyi, M. Berger, 2019, Nature Genetics.

Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction

J. Lippincott-Schwartz, P. Sengupta, C. Klebanoff, 2016, Nature Communications.

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

C. Klebanoff, N. Restifo, D. Palmer, 2005, Trends in immunology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest

James J. Morrow, F. Marincola, M. Raffeld, 2014, Cancer Immunology Research.

Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).

M. Morris, H. McArthur, C. Klebanoff, 2019, Journal of Clinical Oncology.

Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy.

F. Marincola, W. Leonard, P. Muranski, 2016, Cell metabolism.

CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

S. Rosenberg, C. Klebanoff, C. Piccirillo, 2005, The Journal of Immunology.

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

W. Burns, S. Rosenberg, P. Muranski, 2011, Blood.

miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines

T. Waldmann, W. Telford, C. Klebanoff, 2014, Proceedings of the National Academy of Sciences.

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

S. Rosenberg, D. Powell, R. Nussenblatt, 2008, Proceedings of the National Academy of Sciences.

Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells

C. Klebanoff, N. Restifo, 2016, Cell.

Less, but better: A simplified design for T cell redirection and conditional payload delivery.

C. Klebanoff, Korbinian N. Kropp, 2022, Cancer cell.

Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cells

C. Klebanoff, N. Restifo, Tori N. Yamamoto, 2014, Nature Reviews Clinical Oncology.

Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform

D. Scheinberg, C. Klebanoff, Aaron Y. Chang, 2019, bioRxiv.

Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform

D. Scheinberg, C. Klebanoff, Aaron Y. Chang, 2018, Cancer Immunology Research.

496 Toxicity of an Fc engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable anti-tumor immunity in patients

M. Robson, C. Klebanoff, J. Ravetch, 2021, Journal for ImmunoTherapy of Cancer.

Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation.

G. Nabel, C. Klebanoff, R. Sékaly, 2015, Vaccine.

A Phase I study of an HLA-DPB1*0401-restricted T cell receptor targeting MAGE-A3 for patients with metastatic cancers

S. Rosenberg, C. Klebanoff, J. Yang, 2015, Journal of Immunotherapy for Cancer.

Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)

P. Ascierto, T. Kirchhoff, B. Fox, 2023, Journal of Translational Medicine.

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.

I. Ostrovnaya, N. Katabi, A. Ho, 2023, Nature medicine.

The resting state of the human T-cell receptor

T. Walz, C. Klebanoff, Søren Heissel, 2023, bioRxiv.

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer

S. Rosenberg, C. Klebanoff, N. Restifo, 2004, Journal of leukocyte biology.